Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
April 5, 2021 Cover
Volume 99, Issue 12
By addressing problems with interleukin-2's toxicity and half-life, drug companies hope to build a safer, more targeted immunotherapy for cancer or autoimmune diseases
Cover image:This cytokine can be used to treat cancer or autoimmunity, but scientists have to overcome what makes it dangerous
Credit: Yang H. Ku/C&EN/Protein Data Bank/PDB ID 1M47/Shutterstock
IL-2 treatment can be dangerous. Here’s how drug firms are trying to fix it
By addressing problems with interleukin-2's toxicity and half-life, drug companies hope to build a safer, more targeted immunotherapy for cancer or autoimmune diseases
Structural biologists clean up SARS-CoV-2 protein structures
For the past year, the Coronavirus Structural Task Force has been fixing errors in structures of the virus’s proteins to give drug designers the best possible models
Chemical executives use unexpected forum to talk diversity, the environment
The World Petrochemical Conference branches out this year beyond markets and prices
-
Biomaterials engineer Molly Stevens creates materials for tissue regeneration and ultrasensitive diagnostics
She aims to make diagnostics that are scalable and accessible globally
-
A test for the European chemical industry’s green ambitions
But access to post-COVID-19 recovery funds will be key to succeeding
-
Career Ladder: Kelly Chibale
Education helped this organic chemist overcome poverty. He now leads a drug discovery research center in Cape Town
ADVERTISEMENT
ACS Council meets virtually in advance of ACS Spring 2021
Among its actions, ACS Council picks the 2022 candidates for ACS president-elect
